Idiopathic Pulmonary Arterial Hypertension
Conditions
Brief summary
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility data for autologous endothelial progenitor cells (EPCs) injection in patients with IPAH. Yet many questions remain unanswered: what is the ideal quantity of EPCs for therapy, the duration of the therapeutic effect, and moreover, the potential toxicity of such therapy. To help answer these questions, we designed the one year follow-up to investigate the safety and efficacy of autologous EPCs injection in patients with IPAH.
Interventions
Sponsors
Zhejiang University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* The inclusion criteria included a base-line six minute walking distance between 100 and 450 m * A resting mean pulmonary-artery pressure greater than 30 mm Hg * A pulmonarycapillary wedge pressure of less than 15 mm Hg * Pulmonary vascular resistance greater than 240 dyn•sec•cm-5 * 18-60 years old
Exclusion criteria
* The
Countries
China
Outcome results
None listed